全部资讯｜CELL INTELLIGENCE

Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.

PubMed 2026/04/17 发表Mol Ther OncolQ1 · IF 8.5（JCR 2025）

Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy.

PubMed 2026/04/09 发表Mol Ther Adv

Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety.

PubMed 2026/02/27 发表Discov OncolQ3 · IF 2.8（JCR 2025）

OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours.

PubMed 2026/02/25 发表NatureQ1 · IF 56.1（JCR 2025）

The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.

PubMed 2025/11/12 发表LeukemiaQ1 · IF 8.8（JCR 2025）

Engineered natural killer cells for cancer therapy.

PubMed 2025/10/23 发表Cancer CellQ1 · IF 56.1（JCR 2025）

CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer.

PubMed 2025/10/01 发表Clin Cancer ResQ1 · IF 10.9（JCR 2025）

Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.

PubMed 2025/08/21 发表Cancer CellQ1 · IF 56.1（JCR 2025）

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.

PubMed 2025/05/07 发表J Immunother CancerQ1 · IF 11.7（JCR 2025）

Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptors.

PubMed 2025/03/25 发表bioRxiv

全部资讯 19